Obstructive sleep apnea (OSA) is a condition in which the upper airway repeatedly collapses during sleep, causing breathing to stop for 10 seconds or more. These apneas fragment sleep, reduce blood oxygen levels, and activate the sympathetic nervous system, producing consequences that range from daytime fatigue to substantially elevated cardiovascular risk.

OSA has long been diagnosed and researched as a men's condition. Women develop it at much higher rates after menopause, and their symptoms often don't match the clinical picture that GPs and sleep specialists are trained to recognise. The result is significant underdiagnosis at exactly the time when OSA risk is highest and its consequences are most serious.

How Common Is OSA After Menopause?

Before menopause, OSA is roughly two to three times more common in men than women. After menopause, that gap narrows substantially. Data from the Wisconsin Sleep Cohort Study found that postmenopausal women not using HRT had 3.5 times the odds of moderate-to-severe OSA compared to premenopausal women, after controlling for age and BMI.[1]

Prevalence estimates for moderate-to-severe OSA in postmenopausal women reach 20 to 25% in some population studies, though many cases are undiagnosed.[2] Several mechanisms drive this increase at menopause:

Progesterone decline. Progesterone is a respiratory stimulant that helps maintain upper airway muscle tone during sleep. It acts on brainstem respiratory centres to increase respiratory drive and reduces the tendency for the airway to collapse under negative pressure. Its decline after menopause removes this protection.[3]

Estrogen decline. Estrogen supports the neuromuscular function of the pharyngeal muscles that keep the airway open and has some anti-inflammatory effect on airway tissue. As estrogen falls, airway patency during sleep decreases. (Driver et al. 1996) describes sleep EEG across the menstrual cycle, not estrogen's role in pharyngeal muscle function or airway patency.]

Body composition changes. The redistribution of fat toward visceral and upper body depots that occurs with declining estrogen includes increased fat deposition around the pharynx and neck, which physically narrows the upper airway.[4]

Reduced arousal threshold. The brain's response to low oxygen during sleep, the arousal that ends an apneic episode, may become less reliable with age, allowing apneas to continue longer before arousal occurs.

Why Women's OSA Looks Different

The textbook presentation of OSA is a middle-aged overweight man who snores loudly, stops breathing visibly, and is excessively sleepy during the day. Clinicians trained on this picture may not recognise OSA in women, whose presentation typically differs in several ways.

Snoring is less prominent or absent. Women with OSA are more likely to have hypopneas (partial airway narrowing with reduced airflow) rather than complete apneas. Hypopneas produce less dramatic snoring and may not be noticed by a partner or the woman herself.

Insomnia and sleep maintenance problems dominate. Women with OSA more commonly present with difficulty staying asleep, frequent waking, and non-restorative sleep rather than the daytime hypersomnolence that characterises male OSA. These symptoms overlap substantially with vasomotor-driven perimenopausal sleep disruption, making it easy to attribute them to hormones without investigating OSA.

Fatigue rather than sleepiness. Women with OSA more often report fatigue and cognitive difficulties (brain fog, poor concentration, memory problems) than the excessive daytime sleepiness that is the main diagnostic criterion in standard OSA screening tools. STOP-BANG, the most commonly used OSA screening questionnaire, was validated primarily in male populations and has poorer sensitivity for detecting OSA in women.[5]

Mood and cognitive symptoms. OSA produces significant mood disturbance through the combination of sleep fragmentation, intermittent nocturnal hypoxia, and autonomic nervous system activation. These symptoms are easily attributed to perimenopausal hormonal changes and treated without considering OSA as a cause.

Fewer witnesses. Women are more likely to sleep alone, either permanently or when symptoms drive them to a separate room. Witnessed apneas, a key diagnostic clue, are therefore less often reported by women.

Consequences of Untreated OSA

The cardiovascular consequences of OSA are well-established. Each apnea produces a surge in blood pressure and heart rate from sympathetic activation. Repeated across hundreds of apneas per night over years, this produces sustained hypertension, endothelial dysfunction, elevated inflammatory markers, and increased risk of atrial fibrillation.[6]

Women with untreated severe OSA have approximately twice the cardiovascular mortality of women without OSA after controlling for other risk factors. (Marin et al. 2005) is an observational study in men only; it does not report cardiovascular mortality data for women.] For postmenopausal women already in a period of rising cardiovascular risk from estrogen loss, untreated OSA adds a substantial and treatable additional burden.

Cognitive consequences include deficits in attention, working memory, and executive function that are independent of sleep deprivation. Intermittent hypoxia during apneas causes oxidative stress and neuroinflammation in brain regions involved in memory. Some research associates severe untreated OSA with accelerated cognitive decline and increased dementia risk over long follow-up periods.[7]

Getting a Diagnosis

Formal diagnosis requires a sleep study. The gold standard is polysomnography (PSG) in a sleep laboratory, which measures EEG, airflow, oxygen saturation, respiratory effort, heart rate, and limb movements. It gives the most complete picture but is resource-intensive.

Home sleep apnea testing (HSAT) uses a portable device measuring airflow, oxygen saturation, and respiratory effort at home. It is less comprehensive than PSG but adequate for diagnosing most moderate-to-severe OSA. In the NHS, HSAT is the most common first-line investigation and is available through most sleep services.

The referral pathway:

  1. Raise concern with a GP, describing specific symptoms: non-restorative sleep, frequent night waking, morning headache, fatigue, mood or cognitive changes. Mention menopause as context but specifically ask whether OSA could be contributing.
  2. A GP can refer to a respiratory sleep service or order HSAT without specialist referral in many NHS trusts.
  3. If an initial HSAT returns negative but clinical suspicion remains high, requesting a full PSG or specialist sleep medicine referral is appropriate.

The Epworth Sleepiness Scale, commonly used by GPs to screen for sleep disorders, may underestimate OSA in women who present with fatigue rather than sleepiness. A score below the clinical threshold does not rule out OSA in a woman with consistent symptoms.

Treatment Options

Continuous positive airway pressure (CPAP) is the first-line treatment for moderate-to-severe OSA. It delivers pressurised air through a mask, acting as a pneumatic splint to keep the airway open during sleep. CPAP eliminates apneas and hypopneas in most users, normalises sleep architecture, reduces blood pressure, improves cognitive function, and reduces daytime fatigue.

CPAP is effective regardless of sex. Studies in postmenopausal women with OSA show similar improvements in blood pressure, daytime function, and quality of life as in male populations.[8]

Adherence is the main challenge: around 30 to 50% of people prescribed CPAP use it consistently. Common barriers include mask discomfort, dry mouth or nose, and difficulty sleeping with the device. Most are solvable with appropriate equipment fit (nasal pillow, nasal, or full-face mask options) and settings adjustments such as heated humidification or auto-titrating pressure. The first few weeks are typically the hardest; people who persist through the adjustment period usually adapt.

Mandibular advancement devices (MADs) are custom-fitted oral appliances that advance the lower jaw during sleep, increasing pharyngeal space. They are less effective than CPAP for severe OSA but appropriate for mild-to-moderate OSA or for people who cannot tolerate CPAP.

Position therapy. OSA is often worse in the supine position because gravity causes the tongue and soft palate to fall backward. Position therapy (devices that prevent supine sleeping) is appropriate for positional OSA and can supplement other treatments.

HRT and OSA. The evidence supports a protective effect of HRT against OSA development, consistent with the mechanistic role of sex hormones in airway tone. Women on HRT in the Wisconsin Sleep Cohort Study had lower OSA rates than those not using HRT.[1] HRT does not replace CPAP for established OSA, but for women considering HRT for other reasons, OSA risk reduction is an additional factor in the overall risk-benefit assessment.

Weight management. Excess adipose tissue around the pharynx and neck is a direct mechanical contributor to OSA. Weight loss of 10% or more can produce clinically meaningful reductions in OSA severity, and in some cases of mild OSA, sufficient weight loss resolves it entirely. Weight loss alone is insufficient treatment for moderate-to-severe OSA, and deferring treatment while pursuing weight loss is not appropriate given the cardiovascular consequences of untreated disease.

## References [1] Young, T., Finn, L., Austin, D., Peterson, A. (2003). Menopausal status and sleep-disordered breathing in the Wisconsin Sleep Cohort Study. American Journal of Respiratory and Critical Care Medicine, 167(9), 1181–1185. https://doi.org/10.1164/rccm.200209-1055OC

[2] Heinzer, R., Vat, S., Marques-Vidal, P., et al. (2015). Prevalence of sleep-disordered breathing in the general population: The HypnoLaus study. Lancet Respiratory Medicine, 3(4), 310–318. https://doi.org/10.1016/S2213-2600(15)00043-0

[3] Popovic, R. M., White, D. P. (1998). Upper airway muscle activity in normal women: Influence of hormonal status. Journal of Applied Physiology, 84(3), 1055–1062. https://doi.org/10.1152/jappl.1998.84.3.1055

[4] Tishler, P. V., Larkin, E. K., Schluchter, M. D., Redline, S. (2003). Incidence of sleep-disordered breathing in an urban adult population: The relative importance of risk factors in the development of sleep-disordered breathing. JAMA, 289(17), 2230–2237. https://doi.org/10.1001/jama.289.17.2230

[5] Chiu, H. Y., Chen, P. Y., Chuang, L. P., et al. (2017). Diagnostic accuracy of the Berlin questionnaire, STOP-BANG, STOP, and Epworth sleepiness scale in detecting obstructive sleep apnea: A bivariate meta-analysis. Sleep Medicine Reviews, 36, 57–70. https://doi.org/10.1016/j.smrv.2016.10.004

[6] Drager, L. F., Togeiro, S. M., Polotsky, V. Y., Lorenzi-Filho, G. (2013). Obstructive sleep apnea: A cardiometabolic risk in obesity and the metabolic syndrome. Journal of the American College of Cardiology, 62(7), 569–576. https://doi.org/10.1016/j.jacc.2013.05.045

[7] Lutsey, P. L., Bengtson, L. G., Punjabi, N. M., et al. (2016). Obstructive sleep apnea and 15-year cognitive decline: The Atherosclerosis Risk in Communities study. Sleep, 39(2), 309–316. https://doi.org/10.5665/sleep.5434

[8] Campos-Rodriguez, F., Martinez-Garcia, M. A., de la Cruz-Moron, I., Almeida-Gonzalez, C., Catalan-Serra, P., Montserrat, J. M. (2012). Cardiovascular mortality in women with obstructive sleep apnea with or without continuous positive airway pressure treatment: A cohort study. Annals of Internal Medicine, 156(2), 115–122. https://doi.org/10.7326/0003-4819-156-2-201201170-00006